Consider how integrated response technologies and electronic clinical outcomes assessments can improve configurability, study start-up, and flexible mid-study changes.

A look at implementing randomization mid-trial by reconstructing subject and inventory records without disrupting sites or compromising data integrity.

Effortlessly conduct multi-center clinical trials worldwide for drug development with Castor’s EDC and CDMS platforms, including eCOA, ePRO, EHR eSource, eConsent, and IRT modules.

Explore how analytics are revolutionizing clinical trial risk management and shaping the future of risk mitigation.

Performance metrics for supporting risk-based management can be great, however, this author tells readers why collecting and analyzing data after a study has begun may not be the best approach.

Tanya du Plessis, VP of Data Solutions and Strategies at Bioforum, and Rich Davies, VP of Solutions Expert at CluePoints, explain the principle applications of RBQM to Data Management.

Consider how integrated response technologies and electronic clinical outcomes assessments can improve configurability, study start-up, and flexible mid-study changes.

Uncover how an emerging biopharmaceutical company was able to expedite the initiation of a Phase 1 oncology trial for a novel treatment targeting relapsed/refractory multiple myeloma.

Better understand how the evolving landscape drives innovation, why your data capture strategy needs the right technology foundation, and what to look for in a CDMS/EDC system for early-phase oncology.

Re-evaluate your compliance roadmap by exploring expert perspectives on navigating regulatory shifts, distinguishing core surveillance obligations, and building a defensible, value-driven clinical data strategy.

UK trial regulations have been overhauled. Learn what faster approval pathways, stricter publication rules, and longer retention requirements mean for your operations.

A clear guide to U.S. coverage, regulation, and reimbursement: who decides care, how products gain access, and how policy and financing shape cost, value, and patient access.

Delays in site payments, participant reimbursements, and logistical inefficiencies can create roadblocks for patients and sites.

Late or missing reimbursements push patients out of trials. Real-time, flexible payments help keep them engaged and reduce site workload.

Financial stability is critical for trial sites, yet many sites grapple with substantial payment delays. To mitigate these challenges, it's imperative to reassess traditional payment practices,